Omega Packaging Corp failed to test hand sanitizer ingredients and validate processes, FDA found.
What happened
FDA inspected the Totowa, NJ facility from October 18 to November 17, 2022. It found the company did not test incoming ingredients for identity, did not test its active ingredient for methanol or glycerin for diethylene glycol (DEG), and relied on certificates of analysis (COAs) from unqualified suppliers. FDA also found missing process and water-system validation, inadequate quality-unit oversight, and no response to the Form FDA 483 (the inspection observation list).
What FDA found
Failed to test incoming components for identity and specifications, including not testing the active ingredient for methanol or ensuring glycerin was tested for diethylene glycol (DEG).
21 CFR 211.84(d)(1) and 211.84(d)(2)Failed to validate the manufacturing processes used for its drug products.
21 CFR 211.100(a)Failed to validate the water system and lacked written procedures for water-system validation.
21 CFR 211.100(a)The quality unit did not adequately oversee manufacturing, including cleaning validation, stability testing, data integrity controls, batch records, and written quality procedures.
21 CFR 211.22; 21 CFR 211.67(b), 211.166(a), 211.68(b), 211.188, 211.22(d)Failed to provide data supporting how often the water system was tested for resistivity and microbiological growth.
21 CFR 211.84(d)(1) and 211.84(d)(2)
What FDA wants
FDA tells the company to respond in writing within 15 working days with what it has done and will do to correct the violations and prevent recurrence. It also asks for a data-integrity investigation, risk assessment, CAPA plan, and a statement on whether it will keep manufacturing drugs, and recommends a qualified consultant and six-system audit.
Who should pay attention
- brands that contract with Omega to make hand sanitizer
- companies buying OTC hand rub or ethanol/glycerin drug products
- quality teams that rely on supplier COAs without identity testing
This is a summary. Read the original letter on fda.gov.